Vijaya Diagnost. (VIJAYA)

FairStock Score: 57/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Strong growth: sales up 19.44% and profit up 17.69%, with latest quarter sales at ₹205 Cr and net profit at ₹43 Cr.
• High return on capital: ROE 20.07% and ROCE 20.91% indicate efficient use of shareholder funds.
• Healthy balance sheet: Debt/Equity 0.40, Altman Z-Score 6.89, and Piotroski F-Score 8/9 point to financial stability.
• Positive free cash flow of ₹43 Cr and promoter holding of 52.60% show some financial discipline and alignment.

Concerns

• Extreme valuation: P/E 64.42, P/B 13.31, and EV/EBITDA 94.32 leave no margin of safety.
• Price of ₹1029.50 is far above Graham Number ₹164.86 and DCF intrinsic value ₹190.21, with margin of safety at -509%.
• FCF of ₹43 Cr is tiny relative to market cap of ₹10,336 Cr, implying a very low cash yield for investors.
• Dividend yield of only 0.20% provides negligible income while waiting for growth to justify the price.

AI Analysis

As a value investor, I first ask: what does this business yield in cash and earnings, and at what price? Vijaya Diagnost grows well—sales up 19.44%, profit up 17.69%, latest quarter ₹205 Cr sales and ₹43 Cr net profit. ROE 20.07% and ROCE 20.91% show decent capital allocation, and Piotroski F-Score 8/9 suggests solid fundamentals. Debt/equity 0.40 and Altman Z 6.89 reassure me the balance sheet isn't dangerous. Promoter holding 52.60% is helpful. But here is the problem: I am a buyer at a price, not of a good story alone. At ₹1029.50, the market cap is ₹10,336 Cr, which is 64.42 times earnings. The DCF value given is ₹190.21, Graham Number ₹164.86, and the margin of safety is -509%. I cannot call that an investment; it is speculation. EV/EBITDA 94.32 is far beyond any margin of safety. Dividend yield 0.20% means I am paid almost nothing while waiting. Free cash flow of ₹43 Cr against a ₹10,336 Cr market cap gives a microscopic FCF yield. Even a fast grower must eventually justify price with cash profits; at 64 times earnings, Mr. Market expects perfection for many years. Growth of 17.69% is excellent, but it does not support such a valuation. If this were a private business, would I pay 64 times earnings? No. Graham taught me to weigh the margin of safety; here it is negative, not just absent. The score of 44/100 mixed seems fair—the business is okay, but the price is not. I will keep it on a watch list, not in my portfolio. If the market offers a significantly lower price, or if earnings grow into the valuation over many years, I might reconsider. For now, discipline requires walking away.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer